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There is interest in estimating and attributing temporal changes in incidence of breast cancer in relation to the initiation of screening
programmes, in particular to estimation of overdiagnosis of breast cancer as a result of screening. In this paper, we show how
screening introduces complexities of analysis and interpretation of incidence data. For example, lead time brings forward time- and
age-related increases in incidence. In addition, risk factors such as hormone replacement therapy use have been changing
contemporaneously with the introduction of screening. Although we do not indicate exactly how such complexities should be
corrected for, we use some simple informal adjustments to show how they may account for a substantial proportion of increased
incidence, which might otherwise erroneously have been attributed to overdiagnosis. We illustrate this using an example of analysis of
breast cancer incidence data from Sweden.
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In the 1990s, many countries experienced substantial increases in
breast cancer incidence (Chu et al, 1996; Botha et al, 2003),
whereas since 2002, it has fallen in the USA (Ravdin et al, 2007),
both being subjects of the study (Glass et al, 2007). The recent
decline was mostly attributed to a lower prevalence of hormone
replacement therapy (HRT) use (Ravdin et al, 2007), whereas the
levelling off of screening mammography rates in the late 1990s has
been suggested as contributing (Glass et al, 2007). In relation to
increased incidence in the 1990s, this is usually attributed to the
introduction of mammographic screening (Jonsson et al, 2005;
Seppa ¨nen et al, 2006). It is well established that this causes an
immediate rise in incidence, mainly due to the early diagnosis of a
many prevalent asymptomatic cancers (Jonsson et al, 2005;
Svendsen et al, 2006). Also important is overdiagnosis, that is,
the detection by screening of cancer which would never have been
diagnosed in the host’s lifetime if screening had not taken place
(Olsen et al, 2006; Paci et al, 2006; Biesheuvel et al, 2007),
estimated rates of overdiagnosis, ranging from around 3 to 50% or
more (Biesheuvel et al, 2007).
In estimating overdiagnosis either in primary research or in
reviews, the complexities in interpreting cancer incidence data in
the epoch of screening are important (Paci and Duffy, 2005). For
example, one of the present authors (Jonsson et al, 2005) identified
an excess incidence in the screening epoch in Sweden, which
remains unexplained, but specifically did not attribute this to
overdiagnosis. Indeed, the authors cited a number of other
influences, including the prevalence screen effect mentioned above
and potential changes in risk-factor prevalence, notably the use of
HRT. Nevertheless, certain studies have interpreted the above
results as direct estimates of overdiagnosis (Biesheuvel et al, 2007;
Glass et al, 2007).
This potential overinterpretation of incidence patterns is
symptomatic of the difficulty in estimating overdiagnosis in the
context of disease screening. Before screening was initiated, breast
cancer incidence was increasing in many countries (Ravdin et al,
2007). However, the complex interaction among increasing
incidence, lead time, age at diagnosis and calendar period of
diagnosis is often poorly appreciated (Paci and Duffy, 2005). Here,
we describe the complexities of the incidence/screening relation-
ship and illustrate their potential to explain substantial increases in
incidence, using one study as an illustration (Jonsson et al, 2005).
MATERIALS AND METHODS
Screening and incidence
In the first instance, it should be noted that before the introduction
of screening, breast cancer incidence was rising in many parts
of the world (Pisani, 1992) so that any estimate of excess
incidence associated with screening should take such trends
into account (Jonsson et al, 2005). In addition, changes in risk-
factor prevalences contemporaneous with the advent of screening
may add to underlying incidence beyond the prescreening time
trend. A prime example of this is the two- to threefold increase in
HRT use in Sweden between the early 1980s and the early 1990s
(Søgaard et al, 2000). As we shall see below, the interrelationship
between time trends and the effect of screening can be
complicated.
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a target population are offered screening for the first time, a major
rise in incidence is observed. The randomised trials show that
around 3 years of incidence is harvested at the first screen in
women aged 50 or above (Tabar et al, 1992). Thus, if it takes 2
years to carry out the prevalence screen, around a 100% increase in
incidence will be observed during the period. This is an important
component of the evidence for the estimated duration of the
preclinical screen-detectable period, which is typically 2–4 years
(Paci and Duffy, 1991; Tabar et al, 1992). This is largely not
overdiagnosis, but early diagnosis, as is evidenced by the fact that
incidence of interval cancers in the screened population thereafter
is lower than the expected total incidence in the absence of
screening (Tabar et al, 1992). The interpretation (Biesheuvel et al,
2007) of one reported prevalence screen effect (Jonsson et al, 2005)
as ‘overdetection’ (Biesheuvel et al, 2007) indicates that this is still
not fully appreciated.
What is even less well appreciated is the fact that a lead-time
effect persists beyond the introductory phase of screening. Even if
there were no overdiagnosis at all, the incidence would not return
to, or fall below, that expected in the absence of screening until
after the cohort screened has passed beyond the upper age limit for
screening. This is due to several factors, but three of them are
particularly often neglected:
(1) Prevalence screening of women reaching the lower age limit of
the screening programme. Seven years or more after the start
of screening in Sweden, a 54% increase of breast cancer
incidence was observed at ages 50–59 (Jonsson et al, 2005).
Several Swedish counties, however, started screening at age 50,
so this will not be purely incidence screening, and there will
also be prevalence screening of women aged 50–51, a point
raised in this paper.
(2) Increased age-specific incidence due to lead time. If screening
confers an average lead time of 3 years on screen-detected
cancers and two-thirds of cancers diagnosed in the pro-
gramme are screen detected, the average lead time in the
programme will be 2 years. This means that age 52 incidence
will be observed at age 50, age 53 incidence at age 51 and so
on. As incidence increases with age, this will artificially
increase the observed age-specific incidence.
(3) Increased incidence due to anticipation of the temporal trend.
As noted above, in almost all countries where mammographic
screening is common, breast cancer incidence was increasing
over time before the programme started. With a 2-year average
lead time, we will observe 1995 incidence in 1993, 1996
incidence in 1994 and so on, again artificially inflating the
observed incidence.
Figure 1 shows the incidence of breast cancer in England and
Wales in 1985 and 1995, plus a third line representing the expected
incidence in 1995 based on incidence trends in 1980–86, before
screening was started. The first intuitive interpretation of such a
graph is to interpret the vertical differences as increased incidence.
However, in the age range covered by screening, 50–64, it is
instructive to consider the horizontal differences. These will be a
product of the three lead-time phenomena noted above, together
with genuine underlying changes in risk-factor prevalence which
may have caused an increased incidence with time, and over-
diagnosis. The important point to note is that estimation of
overdiagnosis should take into account the lead-time phenomena
in addition to overdiagnosis and changes in incidence.
Example – breast cancer incidence in Sweden, ages 50–69
In the study of incidence in eleven counties in Sweden, with a
target population for screening of 463405 women, it was estimated
that 7 years or more after the initiation of screening at ages 50–59,
the breast cancer incidence relative to that expected from
prescreening trends was 1.69, a 69% excess (Jonsson et al, 2005).
After a lead-time adjustment involving moving some cases in the
age group 40–49 to the 50–59 group and some from the 50–59 to
the 60–69 age group, the relative incidence was 1.54.
RESULTS
To consider the possible contribution to the raw figure of 1.69 of
some of the complexities referred to above, we first remove the
effects of the prevalence screening of those reaching age 50. In the
prevalent phase, the excess incidence was 84%. The counties
starting screening at age 50 comprised around 26% of the
population, and within these counties, 20% of the screens at ages
50–59 were estimated to be prevalence screens. If x denotes the
increased incidence excluding prevalence screens, we have:
0:26 0:2 1:84 þð 1   0:26 0:2Þ x ¼ 1:69
This solves to give x¼1.68, a very minor change.
Next, with respect to the effect of lead time on age-specific
incidence, incidence in the absence of screening increases by
around 64% between age groups 50–59 and 60–69 (Jonsson et al,
2005). A 2.4-year lead time as estimated in that study for this age
group therefore corresponds to a 13% increase in incidence.
Dividing 1.68 by 1.13 gives a figure of 1.49. This method implicitly
replaces the incidence in the age group 50–59 by that in the group
2.4 years older than this, without physically shifting cases between
age groups in the analysis.
To consider an adjustment for use of HRT, this increased the
female population as a whole from around 1.2% to around 4.0%
between 1985 and 1995 (Søgaard et al, 2000). If we assume that
around half of HRT use occurred in the 13% of the population
aged 50–59, this would imply an increase from 4.6 to 15.3% in the
period. Using the estimated relative risk of 1.66 with current HRT
use from the million women study (Beral et al, 2003), and a
method for aggregate exposure measures (Duffy et al, 2007), this
would mean a 7% increase in risk due to HRT; dividing the 1.49 by
1.07 gives a relative incidence of 1.39, a 39% excess.
DISCUSSION
We have described some of the complexities of interpretation and
analysis in estimation of overdiagnosis in breast cancer screening,
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Figure 1 Age-specific breast cancer incidence in the UK in 1985, before
the screening programme, and 1995, during the screening programme, with
expected incidence in 1995 calculated from incidence trends observed
before the breast screening programme began.
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2005). The 39% excess is considerably smaller than the 54%
estimated by the lead-time adjustment of simply shifting of a
number of cases by age group. It is still a rough approximation,
and we do not claim that it is the correct estimate of overdiagnosis.
It relies on a number of assumptions, and is based on invasive
cancer incidence alone: inclusion of ductal carcinoma in situ
might give larger estimates of excess incidence. It does, however,
illustrate that adjustment for some of the complexities in incidence
by time and age and in screening-induced lead time can account
for a substantial proportion of any observed excess incidence
coincident with screening, before any consideration of over-
diagnosis is necessary. It also suggests that the results of the
Swedish study have been overinterpreted as overdiagnosis
estimates by others (Biesheuvel et al, 2007; Glass et al, 2007).
Thus, there are also reasons for believing that much of the 69%
uncorrected excess observed at ages 50–59 in the 7 years post-
screening epoch is largely due to other factors than overdiagnosis.
Also, after the prevalence period, the incidence fell dramatically, as
might be expected, but then equally dramatically rose again to the
prevalence level over the following 6 years (Jonsson et al, 2005). It
is difficult to see how overdiagnosis rates should fall and then rise
again in this manner.
The fact that lead time and related phenomena are likely to
continue to inflate the observed incidence until after the cohort has
ceased to be screened for some time implies that cumulative
incidence in screened or invited cohorts compared to unscreened
or uninvited is a desirable source of data for estimation of
overdiagnosis. Using cumulative incidence in the Malmo ¨ Trial
study and control groups, followed up until after screening had
ceased in the study group (Zackrisson et al, 2006), overdiagnosis
rates of 7–8% were estimated, considerably more plausible than
observational incidence estimates which did not take full account
of the extent of current and previous screening exposure in the
cohorts studied (Zahl et al, 2004). There are problems of
interpretation of Zackrisson’s results, notably the relatively recent
cessation of screening in one age group, but the results are
certainly more consistent with the disease progression modelling
which explicitly takes lead time into account (Olsen et al, 2006).
Finally, we note that overdiagnosis in this context is an
epidemiological rather than a pathological concept, the definition
of disease concerning what would not have been diagnosed if the
screening had not taken place. It therefore is not necessarily
restricted to in situ or ‘minimal’ invasive cancer, although
intuitively one would expect that the majority of overdiagnosed
cases would be in one of these two categories. Definitive estimation
of overdiagnosis of invasive and in situ carcinoma in breast
screening remains to be done. This paper emphasises that any such
definitive estimation needs to take into account the complexities of
the relationship between screening lead time and patterns of
incidence by time and age. It is likely that after adjusting for these,
overdiagnosis estimates will be smaller than many rates quoted in
the past. The challenge for the future will be the avoidance of
overtreatment of screen-detected and early stage cancers.
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